Damora Therapeutics, Inc. (DMRA)
| Market Cap | 1.47B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -209.84M |
| Shares Out | 60.30M |
| EPS (ttm) | -153.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,690 |
| Open | 25.81 |
| Previous Close | 25.50 |
| Day's Range | 24.26 - 25.93 |
| 52-Week Range | 2.45 - 38.33 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | 43.00 (+76.74%) |
| Earnings Date | Apr 30, 2026 |
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DMRA stock is "Buy." The 12-month stock price target is $43.0, which is an increase of 76.74% from the latest price.
News
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today ...
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in ca...
Damora Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Damora, formerly Galecto, is refocusing on mutant CALR therapies for ET and MF, with a lead antibody asset entering clinical trials this year and a strong financial position. Their differentiated approach targets both Type 1 and Type 2 mutations, aiming for best-in-class efficacy and convenience.
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with b...
Galecto Announces Pricing of $275 Million Underwritten Public Offering
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with b...
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock opti...
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?
Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were trig...
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.
Damora Therapeutics Transcript: M&A Announcement
The acquisition brings a robust pipeline of anti-mutant calreticulin therapies for myeloproliferative neoplasms, supported by $285 million in financing. Integration of complementary assets and leadership aims to accelerate clinical development, targeting a $5 billion-plus market opportunity.
Galecto Announces Acquisition of Damora Therapeutics
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproli...
Galecto Reports Third Quarter 2025 Operating and Financial Results
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today ann...
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto Inc. (NASDAQ:GLTO) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro.
Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble
Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped fro...
Galecto Reports Second Quarter 2025 Operating and Financial Results
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced...
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced ...
Damora Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
A novel dual ENL-YEATS and FLT3 inhibitor, BRM-1420, shows strong preclinical efficacy and safety in AML models, targeting high-risk genetic subsets and menin inhibitor resistance. Clinical trials are planned for 2026, with initial focus on relapsed/refractory AML and future combination strategies prioritized.
Galecto to Participate in Upcoming Investor Conferences
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, toda...
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of ...
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keyt...
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a cli...